Alteration of activation, growth, and atresia of bovine preantral follicles by long-term treatment of cows with estradiol and recombinant bovine somatotropin.
The hypothesis was that long-term treatment of cattle with estradiol (E(2)) and bovine somatotropin (bST) would alter the earliest stages of folliculogenesis. Nonlactating Holstein cows (n = 26) were treated in a 2 x 2 arrangement with E(2) (2 x 24 mg implants, 67.1 +/- 1.4 days) and bST (Posilac, 63.6 +/- 1.5 days). At Day 67 +/- 1.3, one ovary was removed for morphometric and immunohistochemical analysis. For each ovary, 388 +/- 38 microscopic fields (2 x 2 mm) were examined and follicles within each field were classified by histological stage. Fields that contained no follicles were classified as empty. Empty fields (n = 100 per ovary) were further classified as containing no evidence of follicles or containing atretic remnants of follicles. Approximately 30 4-microm sections per ovary were stained for proliferating cell nuclear antigen (PCNA), and 150 fields per ovary were evaluated. Additional sections (n = 10 per ovary) were assessed immunohistochemically for apoptosis, and fluorescence intensity was determined for each follicle. Treatment with bST significantly decreased percentage of empty fields containing atretic remnants. Treatment with E(2) induced activation of follicles as shown by a decrease in percentage of primordial follicles and an increase in percentage of primary follicles as determined by PCNA staining. At the primary follicle stage the combination of bST + E(2) decreased apoptosis as shown by decreased fluorescence intensity. Thus, E(2) induced activation of follicles, bST enhanced survival, and the combination lowered atresia.
Cushman
R A
RA
Department of Anatomy, Physiological Sciences and Radiology, North Carolina State University, Raleigh, North Carolina 27606, USA.
DeSouza
J C
JC
Hedgpeth
V S
VS
Britt
J H
JH
D000818:Animals; D017209:Apoptosis; D002417:Cattle / Q000502:physiology*; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005496:Follicular Atresia / Q000187:drug effects*; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D007150:Immunohistochemistry; D006080:Ovarian Follicle / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis
D004343:Drug Implants; D018809:Proliferating Cell Nuclear Antigen; D019382:Human Growth Hormone; D004958:Estradiol